Fate Therapeutics, Inc.
Symbol: FATE (NASDAQ)
1.00
▼ (-0.50%) -0.005
Company Description:
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Key Stats
- Today's Open: $0.997
- Today's High: $1.015
- Today's Low: $0.995
- Today's Volume: 1.84K
- Yesterday Close: $1
- Yesterday High: $1.04
- Yesterday Low: $0.9511
- Yesterday Volume: 1.75M
- Last Min Volume: 14
- Last Min High: $0.995
- Last Min Low: $0.995
- Last Min VWAP: $0.995
Company Profile
- Name: Fate Therapeutics, Inc.
- Website: https://www.fatetherapeutics.com
- Listed Date: 2013-10-01
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001434316
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $115.33M
- Round Lot: 100
- Outstanding Shares: 115.33M
- Asset Type: CS
RECENT FILINGS FOR FATE
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-08-05 | 4 | View |
| 2025-08-05 | 4 | View |
| 2025-08-04 | 144 | View |
| 2025-08-04 | 144 | View |
| 2025-07-29 | SCHEDULE 13G/A | View |
| 2025-07-03 | 3 | View |
| 2025-07-03 | SCHEDULE 13D/A | View |
| 2025-06-17 | 8-K/A | View |
| 2025-06-04 | S-8 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 8-K | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
| 2025-05-30 | 4 | View |
Latest News on FATE